Clinical trials
Liver Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting liver cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,775 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07179484Recruiting
Study of CT041 for advanced stomach or junction cancer after first treatment
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
BeijingAges 18–75 - NCT07177794RecruitingPhase 3
Toripalimab and capecitabine after chemoradiotherapy for esophageal cancer
This trial tests whether adding the immunotherapy drug toripalimab and the chemotherapy pill capecitabine after standard chemoradiotherapy can help prevent esophageal cancer from coming back. It's for people with squamous cell esophageal cancer that hasn't spread far and who have just finished chemoradiotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+ - NCT05994131RecruitingPhase 1/Phase 2
IN10018 plus targeted therapy for EGFR-mutant lung cancer
This trial tests a new drug called IN10018 combined with a targeted therapy (third-generation EGFR-TKI) for people with advanced EGFR-mutant non-small cell lung cancer. It's designed for different stages of treatment, from first-time therapy to after other treatments have stopped working.
ShanghaiAges 18 years+ - NCT07169552RecruitingPhase 2
HC010 for first-line PD-L1 positive advanced lung cancer
This trial tests a new drug called HC010 as a first treatment for people with advanced non-small cell lung cancer that is PD-L1 positive. It aims to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07165886RecruitingPhase 2/Phase 3
Study of sirolimus and octreotide for advanced neuroendocrine tumors
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07169708Recruiting
Study of nivolumab and chemo before surgery for lung cancer
This trial looks at real-world outcomes in Taiwan for people with resectable non-small cell lung cancer (NSCLC) who get nivolumab combined with chemotherapy before surgery. It aims to understand how well this treatment works and how safe it is.
Kaohsiung CityAges 18 years+ - NCT07173751RecruitingPhase 3
Pumitamig for advanced triple-negative breast cancer
This study tests a new drug called pumitamig for people with a type of breast cancer that is triple-negative or has very low hormone receptors and has come back or spread. It aims to see if pumitamig works better than standard treatment and how safe it is for people who cannot get PD(L)-1 immunotherapy with chemo.
Springdale, ArkansasAges 18 years+ - NCT07173348Recruiting
Hypnosis for managing severe breathlessness
This study tests whether hypnosis sessions can help you feel more in control of your breathlessness. If you have a chronic lung or heart condition and struggle with shortness of breath, you may be able to join a series of 3 hypnosis visits to see if it improves your daily life.
Geneva, Canton of GenevaAges 18 years+ - NCT07162038RecruitingPhase 1
CAR-T cells plus half-matched stem cell transplant for high-risk blood cancer
This trial tests giving special immune cells (CAR-T cells) that target a protein called CD19 on cancer cells, followed by a half-matched stem cell transplant, to treat high-risk blood cancers. The treatment aims to improve outcomes by using the CAR-T cells to reduce disease before the transplant.
Bethesda, MarylandAges 18–75 - NCT07160686RecruitingPhase 3
Blood thinner trial for lung cancer patients on treatment
This trial tests if apixaban, a blood thinner pill, can prevent dangerous blood clots in people with advanced lung cancer who are receiving outpatient chemotherapy or other systemic treatments. It aims to reduce the risk of venous thromboembolism (blood clots in veins) during cancer therapy.
DorchesterAges 16 years+ - NCT07162779Enrolling by invitation
New PET scan for advanced prostate cancer patients
This trial tests a new type of PET scan using a radioactive tracer called [68Ga]DOTA-IR-780-C-4 to see if it can find prostate cancer cells that express a protein called PSMA. If you have advanced prostate cancer that has stopped responding to standard treatments, this scan may help your doctor better understand your cancer and possibly guide future care.
Wuxi, JiangsuAges 18–80 - NCT07162246RecruitingPhase 2
Radiosurgery for large brain tumors and metastases
This trial tests a special high-dose radiation treatment for people who have up to two large brain tumors (metastases) and possibly other smaller ones. The treatment aims to control the tumors while limiting radiation to healthy brain tissue.
Toronto, OntarioAges 18 years+ - NCT07163273RecruitingPhase 2
Alternating chemotherapy for first-line metastatic pancreatic cancer
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
Bay Shore, New YorkAges 18 years+ - NCT07164170RecruitingPhase 2
Study of ABSK043 plus Glecirasib for advanced NSCLC
This trial tests a combination of two experimental drugs, ABSK043 and Glecirasib, for people with a specific type of advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination works better than standard treatments.
Hefei, AnhuiAges 18 years+ - NCT06643585RecruitingPhase 3
Comparing T-DXd to standard therapy for molecular relapse in early breast cancer
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
UlmAges 18–75 - NCT07146074Recruiting
Early radiation vs. observation for high-risk bone metastases
This trial tests whether giving radiation therapy early to high-risk but pain-free or nearly pain-free bone metastases can prevent future problems, compared to waiting and monitoring them. It is for people whose cancer has spread to multiple bones and who have certain risky features in those spots.
Wilrijk, AntwerpAges 18 years+ - NCT07154043Recruiting
Comparing compression pump vs. massage for arm swelling
This study compares two therapies for breast cancer-related arm swelling (lymphedema): one uses a machine that pumps air around your arm (intermittent pneumatic compression, or IPC), and the other is a special type of massage (manual lymph drainage, or MLD). The goal is to see if the machine works as well as or better than massage for reducing swelling.
DenizliAges 18–65 - NCT05761093Recruiting
Share your treatment preferences for metastatic prostate cancer
This study asks people with metastatic prostate cancer and their doctors about what benefits and risks matter most when choosing treatment. Your answers can help improve how treatment options are discussed in Hong Kong.
ShatinAges 18 years+ - NCT06438822RecruitingPhase 2
Immunotherapy plus chemo for advanced bile duct cancer
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
Chengdu, SichuanAges 18–75 - NCT07136545RecruitingPhase 1/Phase 2
HCB101 plus pembrolizumab for advanced head and neck cancer
This trial tests a new drug, HCB101, combined with the immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread and is no longer responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
Taoyuan, Guishan DistrictAges 18 years+ - NCT04224389Recruiting
Radiation plus throat surgery for early tonsil or tongue-base cancer
This study compares ways of treating early squamous cell cancer in the tonsil or the tongue base, using either radiation therapy, transoral (through-the-mouth) surgery, or both. It aims to see which approach works best while keeping cancer under control.
Villejuif, Val De MarneAges 18 years+ - NCT07135856Recruiting
Lung-saving surgery after pre-surgery therapy for NSCLC
This trial studies how well sleeve lobectomy (a type of lung-saving surgery) works for people with non-small cell lung cancer who have already received therapy like chemotherapy or immunotherapy before surgery. It aims to see if this approach is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT03406247RecruitingPhase 2
Immunotherapy after salvage surgery for head and neck cancer
This Phase 2 trial tests an immunotherapy given after salvage surgery for certain head and neck squamous cell cancers that came back (or a new second cancer) in an area that was already treated with radiation. It aims to lower the chance the cancer returns after surgery, especially in higher-risk situations.
Villejuif, Val De MarneAges 18 years+
Hear when a new Liver Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,775 recruiting liver cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Locally Advanced Rectal Cancer
- Locally Advanced Cervical Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.